Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Total Debt: 2009-2024

Historic Total Debt for Northwest Biotherapeutics (NWBO) over the last 16 years, with Dec 2024 value amounting to $22.0 million.

  • Northwest Biotherapeutics' Total Debt fell 43.61% to $16.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.9 million, marking a year-over-year decrease of 43.61%. This contributed to the annual value of $22.0 million for FY2024, which is 25.51% down from last year.
  • Per Northwest Biotherapeutics' latest filing, its Total Debt stood at $22.0 million for FY2024, which was down 25.51% from $29.5 million recorded in FY2023.
  • Northwest Biotherapeutics' 5-year Total Debt high stood at $363.5 million for FY2020, and its period low was $22.0 million during FY2024.
  • Its 3-year average for Total Debt is $46.0 million, with a median of $29.5 million in 2023.
  • Its Total Debt has fluctuated over the past 5 years, first spiked by 1,256.21% in 2020, then plummeted by 65.92% in 2023.
  • Yearly analysis of 5 years shows Northwest Biotherapeutics' Total Debt stood at $363.5 million in 2020, then crashed by 63.70% to $131.9 million in 2021, then slumped by 34.40% to $86.5 million in 2022, then plummeted by 65.92% to $29.5 million in 2023, then dropped by 25.51% to $22.0 million in 2024.